1. P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY "RETE EMATOLOGICA PUGLIESE". (5th April 2022) Authors: Mele, G; Cascavilla, N; Di Renzo, N; Guarini, A; Mazza, P; Melillo, L; Pavone, V; Tarantini, G; Curci, P; Falcone, AP; Germano, C; Mele, A; Palazzo, G; Palumbo, G; Reddiconto, G; Rossini, B; Specchia, G; Musto, P; Pastore, D Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 20 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY "RETE EMATOLOGICA PUGLIESE". (5th April 2022) Authors: Mele, G; Cascavilla, N; Di Renzo, N; Guarini, A; Mazza, P; Melillo, L; Pavone, V; Tarantini, G; Curci, P; Falcone, AP; Germano, C; Mele, A; Palazzo, G; Palumbo, G; Reddiconto, G; Rossini, B; Specchia, G; Musto, P; Pastore, D Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 21 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. P27: HUMORAL RESPONSE RATE POST MRNA COVID19 VACCINATION (BNT162B2) IS HIGLY DEPENDENT TO BONE MARROW PLASMACYTOSIS: LONG FOLLOW-UP OF SYMPTOMATIC MULTIPLE MYELOMA PATIENTS. (5th April 2022) Authors: Mele, G; Romano, C; Spina, A; Merchionne, F; Quintana, G; Urbano, M; Pasanisi, AM; Rinaldi, E; Solfrizzi, MP; Romano, A; Guaragna, G; DiNoi, ML; Miccoli, A; Santoro, A; Pastore, D Journal: HemaSphere Issue: Volume 6(2022)Supplement 2 Page Start: 25 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗